Breast Cancer Oncology
Cantargia AB’s clinical research activity is centered on advanced triple negative breast cancer, with interest in treatment strategies for a difficult-to-treat breast cancer subtype lacking common hormone and HER2 targets.
- Triple negative breast cancer
- Advanced solid tumours
- Oncology
The sponsor’s work in this area reflects a focus on therapeutic options for aggressive disease with limited targeted treatment choices.
Immuno-Oncology and Targeted Antibody Therapy
The trial portfolio includes nadunolimab, an investigational antibody-based therapy studied in combination with chemotherapy in metastatic breast cancer settings.
- Monoclonal antibody therapy
- Tumour-directed immunotherapy
- Combination oncology treatment
Research interest in this domain is directed toward biologic approaches that may complement established anticancer regimens.
Chemotherapy Combination Regimens
Cantargia AB is active in studies combining investigational therapy with gemcitabine and carboplatin, indicating a therapeutic interest in chemotherapy-supported treatment for advanced cancer.
- Gemcitabine
- Carboplatin
- Combination treatment in oncology
This area links cytotoxic treatment backbones with novel biologic agents for patients with limited options.
Clinical Development in Solid Tumour Oncology
The sponsor’s research footprint spans a multicentre solid tumour programme involving collaborating sites in Sweden, with emphasis on clinically significant outcomes in breast cancer care.
- Multicentre oncology research
- Solid tumour therapeutics
- Clinical oncology
Its trial activity is concentrated on therapies intended for patients with advanced malignancy requiring systemic treatment.
